Abstract
Background: Administration of pneumococcal conjugated vaccine (PCV13) has been shown to reduce asthma exacerbation along with related effect on IgG/IgE-Abs to S. pneumoniae. Associated comprehensive related cytokine dynamics in BA endotypes are less clear. We aimed to determine the changes in Th1/Th2/Treg cytokines in 31 patients with different BA endotypes after PCV13 immunization.
Methods: ELISA level of IL-4, IL-6, IL-8, IL-10, IL-18, IFN-g, TNF-, MCP-1 measured in serum samples initially, 6 weeks, 6 and 12 months after vaccination. ACT –test and spirometric values have been measured at the same points.
Results: Under clustering of inflammatory BA phenotypes an increase in IFN-g (p<0,05) – up to 1,96 pg/ml [0,00; 2,6]was observed in allergic (Th2) BA 6 weeks from PCV13 administration. On the contrary, in patients with non-Th2 endotype, and asthma with obesity, lower values of IFN-g after 6 weeks (0,00 [0,00; 0,00], (p<0,05)) and 6 months (0,00 [0,00; 0.00], (p<0,05))have been detected. For late-onset Th2 asthma significant increase on IL-10 was observed after 12 months (3,12 [1,00; 8,22]) along with reduced serum IL-6 relative to other patients with late-onset non-Th2 asthma 6 months after vaccination (0,87 [0,66; 0,95](p<0,05).
Conclusion: Beneficial changes in proinflammatory/regulatory cytokines along with clinical effect are dependent from asthma phenotype and stable after 12 months from PCV13 administration especially in late-onset non-Th2 asthma indicating its immunomodulatory potential for further therapeutic strategies.
Footnotes
Cite this article as ERJ Open Research 2022; 8: Suppl. 8, 226.
This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.
This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
